Semaglutide for heart failure improved symptoms and quality of life in obesity-related HFpEF trials, but the drug is not FDA-approved for heart failure.
Semaglutide improved heart failure symptoms, exercise capacity, and quality of life in two major clinical trials of people with obesity-related heart failure with preserved ejection fraction (HFpEF). Semaglutide is not FDA-approved to treat heart failure in the United States, and it does not cure or reverse the condition. Most of the measured benefit appeared in patients who also lost a substantial amount of weight.
What the Research Shows: STEP-HFpEF Trial Results
The STEP-HFpEF program is the main reason cardiologists are paying attention to semaglutide for heart failure. Both trials tested once-weekly semaglutide 2.4 mg, the same dose sold as Wegovy, against a placebo for about one year.
Participants had obesity and HFpEF, meaning their hearts pumped a normal percentage of blood but still caused breathlessness, fatigue, and fluid buildup. About half of the patients in the second trial also had type 2 diabetes.
| Trial | Population | Main results vs. placebo |
|---|---|---|
| STEP-HFpEF (2023) | 529 adults with obesity and HFpEF, no diabetes | Quality-of-life score (KCCQ-CSS) improved about 7.8 points more; 6-minute walk distance about 21 meters farther; body weight fell 13.3% vs. 2.6% |
| STEP-HFpEF DM (2024) | 616 adults with obesity, HFpEF, and type 2 diabetes | KCCQ-CSS improved about 7.3 points more; 6-minute walk distance about 15 meters farther; body weight fell roughly 6% vs. 2% |
| SELECT (2023) | Overweight or obesity with existing cardiovascular disease, no diabetes | 20% lower risk of major cardiovascular events; heart failure analyses also favored semaglutide |
| SOUL (2025) | Type 2 diabetes with heart disease, oral semaglutide 14 mg | 14% lower risk of major cardiovascular events |
The improvements in how patients felt were modest but meaningful, and they showed up within a few months of starting treatment. A 7- to 8-point gain on the KCCQ scale is generally considered a clinically important difference in heart failure research.
HFpEF vs. HFrEF: Why the Type of Heart Failure Matters
Heart failure is not one disease. HFpEF means the heart's ejection fraction is 50% or higher, so the muscle is stiff and slow to relax. HFrEF means the ejection fraction is 40% or lower, and the heart muscle is weak.
The strongest evidence for semaglutide in heart failure comes from patients who have obesity-related HFpEF, and the data in HFrEF are much thinner. Earlier GLP-1 drugs raised concerns about a slight rise in heart rate, which matters more when the pump is already weak.
Guideline-directed therapy for HFrEF, including beta blockers, ARNI drugs, and SGLT2 inhibitors, remains the foundation of treatment. Semaglutide has not replaced any standard heart failure medication in any clinical trial.
How Semaglutide May Help the Heart
No study has proven that semaglutide directly repairs heart muscle. The leading explanation is that it helps the heart indirectly.
- Weight loss: Dropping 10% or more of body weight reduces fat around the heart and lowers the workload on a stiff left ventricle.
- Less inflammation: C-reactive protein, a marker of systemic inflammation, fell by roughly 40% in STEP-HFpEF.
- Better blood pressure and blood sugar: Both are common drivers of heart failure symptoms.
- Possible direct effects: GLP-1 receptors exist in the heart and blood vessels, but a direct benefit remains unproven in humans.
Other researchers are pursuing different targets. Investigators working on elamipretide heart failure research are focusing on mitochondrial energy production, but that approach remains experimental and has not produced the same signal as semaglutide.
Is Semaglutide FDA-Approved for Heart Failure?
No. Semaglutide is not FDA-approved for heart failure, and no GLP-1 medication currently carries that indication.
Wegovy is approved for chronic weight management and to reduce cardiovascular risk in adults with obesity and existing heart disease. Ozempic and Rybelsus are approved for type 2 diabetes, and Ozempic also carries a cardiovascular risk-reduction indication. Semaglutide oral for weight loss is a growing area of interest as well, with higher daily tablet doses tested in people with obesity.
Using semaglutide to treat HFpEF is therefore an off-label decision, made case by case between a patient and a prescribing clinician.
Dosing: Heart Failure Trials vs. Weight Loss
The heart failure trials used the standard obesity dose of 2.4 mg injected once weekly. That dose is reached by slowly increasing from a low starting point over about 16 weeks.
The starting dose of semaglutide for weight loss is 0.25 mg once weekly for four weeks. It then steps up to 0.5 mg, 1 mg, 1.7 mg, and finally 2.4 mg, with at least four weeks at each step.
A frequent question is why increase dose of semaglutide for weight loss, and the answer is that appetite suppression and total weight loss generally grow with each step up, while side effects are managed by moving slowly.
The semaglutide tablet dose for weight loss is not the same as the diabetes tablets. Rybelsus comes in 3 mg, 7 mg, and 14 mg strengths for type 2 diabetes, while obesity studies used 25 mg and 50 mg taken once daily.
| Product | Form | Typical dose | FDA-approved use |
|---|---|---|---|
| Wegovy | Weekly injection | 2.4 mg | Chronic weight management; cardiovascular risk reduction |
| Ozempic | Weekly injection | 0.5–2 mg | Type 2 diabetes; cardiovascular risk reduction |
| Rybelsus | Daily tablet | 3–14 mg | Type 2 diabetes |
Safety, Side Effects, and Questions for Your Doctor
Semaglutide is generally tolerable, but people with heart failure often take several medications and are more sensitive to dehydration from vomiting or diarrhea.
- Common: nausea, vomiting, diarrhea, constipation, and abdominal pain, usually worst in the first few weeks.
- Serious: pancreatitis, gallbladder disease, bowel obstruction, and gastroparesis.
- Boxed warning: thyroid C-cell tumors observed in rodents; the relevance to humans is unknown.
- Avoided in: a personal or family history of medullary thyroid cancer or MEN2 syndrome, and during pregnancy.
- Muscle loss: rapid weight loss can reduce lean mass, which is a real concern in frail older adults with heart failure.
Compounded semaglutide is not FDA-approved, and its quality varies. You will find plenty of semaglutide with b12 for weight loss reviews online because some compounding pharmacies add vitamin B12, but those products have not been tested for safety or effectiveness the way brand-name drugs have.
Bring these questions to your cardiologist before starting any GLP-1 drug:
- Is my heart failure HFpEF or HFrEF, and does that change your recommendation?
- Would weight loss help my symptoms no matter how I lose the weight?
- Do any of my current medications interact with semaglutide?
- What should I do if I become dehydrated or can't keep fluids down?
Semaglutide looks genuinely promising for obesity-related HFpEF, but it is a metabolic and weight-management drug rather than a heart failure cure. Anyone considering it should talk with a cardiologist or prescribing clinician first, and standard heart failure treatment should continue either way.
Frequently Asked Questions
Can semaglutide be used to treat heart failure?
Semaglutide is not FDA-approved to treat heart failure, so any such use is off-label. In the STEP-HFpEF trials, once-weekly semaglutide 2.4 mg improved heart failure symptoms, exercise capacity, and quality of life in patients with obesity-related HFpEF compared with placebo.
Which type of heart failure does semaglutide help?
The clearest benefit has been shown in heart failure with preserved ejection fraction (HFpEF) combined with obesity. Evidence in heart failure with reduced ejection fraction (HFrEF) is limited, and standard guideline-directed therapy remains the main treatment for that type of heart failure.
What dose of semaglutide was used in the heart failure trials?
Both STEP-HFpEF trials used 2.4 mg of injectable semaglutide once weekly, the same dose approved for chronic weight management. Patients typically reach that dose by starting at 0.25 mg weekly and increasing gradually over roughly 16 weeks.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.